EyePoint Pharmaceuticals Inc
EYPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.16B
Close$
$-1.91
114.2% downside
Current Fair Value
114.2% downsideOvervalued by 114.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.16 Billion |
|---|---|
| Enterprise Value | $1.08 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.17 |
| Beta | 1.74 |
| Outstanding Shares | 86,543,000 |
Return
| Return on Equity | -184.27% |
|---|---|
| Return on Assets | -134.38% |
| Return on Invested Capital | -168.63% |
Valuation & Multiples
| P/E Ratio | -3.71 |
|---|---|
| PEG | -6.3 |
| Price to Sales | - |
| Price to Book Ratio | 13.48 |
| Enterprise Value to Revenue | 385.97 |
| Enterprise Value to EBIT | -3.43 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-1.01
Average shareholder expectationRevenue Estimate
$451,214
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$245,929
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 35.01% |
|---|---|
| Total Calls | 269▼ 99.98% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.70%▼ 89.06% |
|---|---|
| Total Invested | $217.60M▼ 80.93% |
| Investors Holding | 52▼ 151.00% |
ESG Score
No data